HER3广泛存在于许多重要实体肿瘤,如肺癌、乳腺癌和结直肠癌等,并被证实是介导EGFR靶向治疗药物耐药的关键位点。 然而,过去尚无获批上市的针对HER3的靶向治疗药物,而且许多单克隆抗体类药物在临床研究中显示的疗效有限而终止了研发,因...
在2023年6月美国临床肿瘤学会(ASCO)会议上,张力教授牵头的 first-in-class EGFRxHER3 双特异性 ADC的首项人体 I 期临床研究「BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with loc...
[10] L. Zhang, Y. Ma, Y. Zhao, et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 2023 ASCO Abstract 3001.[11] L. Zhang, Y. Ma, Y....
本次美国临床肿瘤学会(ASCO)年会,中山大学肿瘤防治中心张力教授带来一项国产 first-in-class EGFRxHER3 双特异性ADC 的首项人体 I 期临床研究「BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a ...
[1]Li Zhang, Yuxiang Ma,et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.presented at ASCO 2023. ...
近年来,ADC类药物在肺癌、乳腺癌等癌种中的发展极为迅猛,也为HER3靶向治疗提供了全新选择,而选用双特异性抗体同时靶向EGFR和HER3,则有望实现「一石二鸟」,以破解EGFR靶向药物的治疗耐药,并实现协同增效、强力抑癌,在疗效上超越仅靶向EGFR或HER3二者之一的ADC类药物,这也是BL-B01D1的设计出发点。
资料5、BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study 声明:以上内容仅供参考,不构成投资建议。
资料5、BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study 声明:以上内容仅供参考,不构成投资建议。
本次美国临床肿瘤学会(ASCO)年会,中山大学肿瘤防治中心张力教授带来一项国产 first-in-class EGFRxHER3 双特异性ADC 的首项人体 I 期临床研究「BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a...
BL-B01D1 是一种首创性的新型ADC,由EGFR x HER3双特异性抗体和新型TOP-I抑制剂通过可裂解连接体相结合而成。该研究旨在探索BL-B01D1 治疗非小细胞肺癌(NSCLC)患者的疗效和安全性,研究者在本次ESMO大会上报告I期研究的最新结果。 研究方法 该研究的入组标准包括局部晚期或转移性NSCLC或其他实体瘤患者,患者的...